The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer - the SERAPHINA study

Chemotherapies are still widely used in advanced breast cancer, specifically in patients with HER2-negative disease. This non-interventional real-world study assessed the utilization of nab-paclitaxel in a broad patient population with advanced breast cancer.

Bibliographic Details

Main Authors:	Schneeweiss, Andreas (Author) , Fasching, Peter A. (Author) , Thill, Marc (Author) , van Mackelenbergh, Marion (Author) , Marmé, Frederik (Author) , Tesch, Hans (Author) , Fehm, Tanja N. (Author) , Park-Simon, Tjoung-Won (Author) , Häberle, Lothar (Author) , Uhrig, Sabrina (Author) , Tome, Oliver (Author) , Spall, Thomas (Author) , Theuser, Anna-Katharin (Author) , Ruebner, Matthias (Author) , Belleville, Erik (Author) , Wallwiener, Diethelm (Author) , Brucker, Sara Y. (Author) , Hartkopf, Andreas D. (Author)
Format:	Article (Journal)
Language:	English
Published:	19 June 2025
In:	Journal of cancer research and clinical oncology Year: 2025, Volume: 151, Issue: 6, Pages: 1-11
ISSN:	1432-1335
DOI:	10.1007/s00432-025-06246-2
Online Access:	Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00432-025-06246-2 Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s00432-025-06246-2
Author Notes:	Andreas Schneeweiss, Peter A. Fasching, Marc Thill, Marion van Mackelenbergh, Frederik Marme, Hans Tesch, Tanja N. Fehm, Tjoung-Won Park-Simon, Lothar Häberle, Sabrina Uhrig, Oliver Tome, Thomas Spall, Anna-Katharin Theuser, Matthias Ruebner, Erik Belleville, Diethelm Wallwiener, Sara Y. Brucker, Andreas D. Hartkopf